Inhibrx (INBX) Director Kimberly Manhard Sells 1,500 Shares

What Happened Kimberly Manhard, a director of Inhibrx Biosciences, sold a total of 1,500 INBX shares in three open‑market transactions between Sept 11 and Sept 15, 2026. The sales were: 500 shares on 2026-09-11 at $111.78 ($55,888), 500 shares on 2026-09-14 at $110.26 ($55,130), and 500 shares on 2026-09-15 at $105.05 ($52,525), for combined proceeds of $163,543. These were sales (not purchases or option exercises), which are often routine and do not by themselves indicate company outlook.

Key Details

• Transaction dates and prices:
  • 2026-09-11: 500 shares @ $111.78 — $55,888
  • 2026-09-14: 500 shares @ $110.26 — $55,130
  • 2026-09-15: 500 shares @ $105.05 — $52,525
• Total shares sold: 1,500; total proceeds: $163,543.
• Shares owned after transaction: Not specified in the filing provided.
• Footnote: The shares are directly owned by the Kimberly Joan Manhard Revocable Trust (dated 6/4/2012). Manhard is a trustee and may be deemed to indirectly beneficially own those securities.
• Filing timeliness: Form 4 was filed on 2026-09-15 reporting transactions through 2026-09-15; this appears to be within the standard two‑business‑day reporting window (timely).

Context

• These were open‑market sales (code S) rather than purchases or option exercises. Sales by insiders can be for many reasons (diversification, tax planning, trust management) and are not necessarily a signal about company fundamentals.
• The trust ownership footnote means the reported holdings are held in a revocable trust for which Manhard is trustee; this is an indirect ownership disclosure rather than an institutional investor trade.